Related Experiment Video
Updated: May 25, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Potentiation of anticancer drugs: effects of pentoxifylline on neoplastic cells
Miroslav Barancik1, Viera Bohacova, Lenka Gibalova
1Institute for Heart Research, Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava 840 05, Slovakia.
Abstract:
The drug efflux activity of P-glycoprotein (P-gp, a product of the mdr1 gene, ABCB1 member of ABC transporter family) represents a mechanism by which tumor cells escape death induced by chemotherapeutics. In this study, we investigated the mechanisms involved in the effects of pentoxifylline (PTX) on P-gp-mediated multidrug resistance (MDR) in mouse leukemia L1210/VCR cells. Parental sensitive mouse leukemia cells L1210, and multidrug-resistant cells, L1210/VCR, which are characterized by the overexpression of P-gp, were used as experimental models. The cells were exposed to 100 μmol/L PTX in the presence or absence of 1.2 μmol/L vincristine (VCR). Western blot analysis indicated a downregulation of P-gp protein expression when multidrug-resistant L1210/VCR cells were exposed to PTX. The effects of PTX on the sensitization of L1210/VCR cells to VCR correlate with the stimulation of apoptosis detected by Annexin V/propidium iodide apoptosis necrosis kit and proteolytic activation of both caspase-3 and caspase-9 monitored by Western blot analysis. Higher release of matrix metalloproteinases (MMPs), especially MMP-2, which could be attenuated by PTX, was found in L1210/VCR than in L1210 cells by gelatin zymography in electrophoretic gel. Exposure of resistant cells to PTX increased the content of phosphorylated Akt kinase. In contrast, the presence of VCR eliminated the effects of PTX on Akt kinase phosphorylation. Taken together, we conclude that PTX induces the sensitization of multidrug-resistant cells to VCR via downregulation of P-gp, stimulation of apoptosis and reduction of MMPs released from drug-resistant L1210/VCR cells. These facts bring new insights into the mechanisms of PTX action on cancer cells.
Insights
Pentoxifylline (PTX) sensitizes multidrug-resistant leukemia cells to chemotherapy by reducing P-glycoprotein (P-gp) expression and promoting apoptosis. PTX also decreases matrix metalloproteinases (MMPs) and affects Akt kinase phosphorylation, offering new insights into cancer treatment mechanisms.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- P-glycoprotein (P-gp) mediates multidrug resistance (MDR) in cancer cells, enabling them to evade chemotherapy.
- Understanding resistance mechanisms is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate how pentoxifylline (PTX) affects P-gp-mediated MDR in mouse leukemia L1210/VCR cells.
- To elucidate the molecular mechanisms underlying PTX's action on drug-resistant cancer cells.
Main Methods:
- Utilized mouse leukemia cell lines L1210 (sensitive) and L1210/VCR (resistant, P-gp overexpressing).
- Treated cells with PTX and vincristine (VCR), analyzing P-gp expression via Western blot.
- Assessed apoptosis using Annexin V/propidium iodide staining and caspase activation.
- Measured matrix metalloproteinases (MMPs) using gelatin zymography.
- Investigated Akt kinase phosphorylation levels.
Main Results:
- PTX treatment downregulated P-gp expression in L1210/VCR cells.
- PTX sensitized cells to VCR, correlating with increased apoptosis and activation of caspase-3 and caspase-9.
- Reduced release of MMPs, particularly MMP-2, was observed with PTX treatment.
- PTX increased phosphorylated Akt kinase, an effect diminished by VCR.
Conclusions:
- PTX sensitizes multidrug-resistant leukemia cells to vincristine by downregulating P-gp.
- PTX promotes apoptosis and reduces MMP release in drug-resistant cells.
- These findings provide novel insights into PTX's mechanisms of action against cancer cells, potentially improving chemotherapy efficacy.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
